Safety profiles of atypical antipsychotics in the elderly

  • David C. Belmonte
  • Joel E. Streim


The advent of atypical antipsychotics has allowed for the treatment of psychosis with improved patient tolerability compared with conventional neuroleptics. Atypicality has been defined in terms of fewer extrapyramidal symptoms, as well as enhanced efficacy against the negative symptoms of schizophrenia. However, the atypical antipsychotics are not a panacea for psychosis; they are not without their own potential for adverse effects. In the geriatric population, the use of antipsychotics has been extended to include the treatment of behavioral sequelae associated with dementia and delirium, especially in the nursing home setting. Compared with their younger counterparts, special consideration must be given for elderly patients in light of physiologic differences associated with aging and an increased prevalence of comorbid medical conditions. These differences can potentially reduce tolerability of these medications. This review examines the evidence for particular adverse effects associated with aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone in the older patient population.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002, 14:123–129.PubMedCrossRefGoogle Scholar
  2. 2.
    Older Americans 2000: key indicators of well-being. Accessed December 7, 2003.Google Scholar
  3. 3.
    Kawas C, Gray S, Brookmeyer R, et al.: Age-specific incidence rates of Alheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54:2072–2077.PubMedGoogle Scholar
  4. 4.
    Greenblatt DJ, Abernathy DR, Shader RI: Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 1986, 8:249–255.PubMedCrossRefGoogle Scholar
  5. 5.
    Shen WW: A history of antipsychotic drug development. Comprehens Psychiatry 1999, 40:407–414.CrossRefGoogle Scholar
  6. 6.
    Herst L, Powell G: Is clozapine safe in the elderly? Aust N Z J Psychiatry 1997, 31:411–417.PubMedGoogle Scholar
  7. 7.
    Sajatovic M, Jaskiw G, Konicki PE, et al.: Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry 1997, 12:553–558.PubMedCrossRefGoogle Scholar
  8. 8.
    Street JS, Clark S, Gannon K, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry 2000, 57:968–976.PubMedCrossRefGoogle Scholar
  9. 9.
    Fontaine CS, Hynan LS, Koch K, et al.: A double-blind comparison of olanzapine versus risperidone in acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003, 64:726–730.PubMedCrossRefGoogle Scholar
  10. 10.
    Hwang JP, Yang CH, Lee TW, Tsai SJ: The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol 2003, 23:113–118.PubMedCrossRefGoogle Scholar
  11. 11.
    Barak Y, Shamir E, Zemishlani H, et al.: Olanzapine versus haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1199–1202.PubMedCrossRefGoogle Scholar
  12. 12.
    Tariot PN, Salzman C, Yueng PP, et al.: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therapeut 2000, 22:1068–1084.CrossRefGoogle Scholar
  13. 13.
    Madhusoodanan S, Brenner R, Alcantra A: Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000, 13:28–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Dogu, O, Sevim S, Kaleagasi HS: Seizures associated with quetiapine treatment. Ann Pharmacother 2003, 37:1224–1227.PubMedCrossRefGoogle Scholar
  15. 15.
    Fernandez HH, Trieschmann ME, Burke MA, et al.: Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Move Disord 2003, 18:510–514.CrossRefGoogle Scholar
  16. 16.
    Takahashi H, Yoshida K, Sugita T, et al.: Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:549–553.PubMedCrossRefGoogle Scholar
  17. 17.
    Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double-blind trial. J Clin Psychiatry 1999, 60:107–115.PubMedCrossRefGoogle Scholar
  18. 18.
    Brodaty H, Ames D, Snowdon J: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003, 64:134–143.PubMedCrossRefGoogle Scholar
  19. 19.
    Physicians’ Desk Reference, edn 58. Montvale, NJ: Medical Economics Company; 2003.Google Scholar
  20. 20.
    De Deyn PP, Rabheru K, Rasmussen MD, et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999, 53:946–955.PubMedGoogle Scholar
  21. 21.
    Zarate CA, Baldessarini RJ, Siegel AJ, et al.: Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997, 58:311–317.PubMedGoogle Scholar
  22. 22.
    Leibson CI, Tosteson AN, Gabriel JE, Melton LJ: Mortality, disability and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002, 50:1644–1650.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • David C. Belmonte
    • 1
  • Joel E. Streim
    • 1
  1. 1.Division of Geriatric PsychiatryUniversity of Pennsylvania Department of PsychiatryPhiladelphiaUSA

Personalised recommendations